

eGFR measurements in clinical practice

Pierre Delanaye, MD, PhD
University of Liège
CHU Sart Tilman
BELGIUM



Category**Disclosure Information**

Employer

Nothing to disclose.

Ownership Interest

Nothing to disclose.

Consultancy

IDS; Nephrolytix; Alentis Therapeutics; ARK Bioscience;

Research Funding

Nothing to disclose.

Honoraria

IDS; Fresenius Kabi; Fresenius Medical Care; Nephrolytix; Alentis Therapeutics; ARK Bioscience;
AstraZeneca;

Patents or Royalties

Nothing to disclose.

Advisory or Leadership Role

Nothing to disclose.

Speakers Bureau

Nothing to disclose.

Other Interests or
Relationships

Nothing to disclose.